All In Biotech

Drug Trial Radar · NCT07229742

A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Active Lupus Nephritis

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Nov 22, 2025

Primary completion

Jun 2027

Study completion Mar 2028

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with lupus nephritis (LN). It adopts a randomized, double-blind, placebo-controlled, multicenter trial design.

Conditions

  • Active Lupus Nephritis

Interventions

  • SHR-2173 InjectionDrug

    SHR-2173 injection.

  • SHR-2173 Injection Blank PreparationDrug

    SHR-2173 injection blank preparation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ratio of 24-hour urine protein-creatinine ratio (24-hour UPCR) to the baseline.Time frame: At Week 24.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The General Hospital of the Eastern Theater Command of the People's Liberation Army of China

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.